Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

41.59
Delayed Data
As of Sep 30
 -0.21 / -0.50%
Today’s Change
41.27
Today|||52-Week Range
59.00
-28.39%
Year-to-Date
Novo Nordisk: Growth at a Good Price
Sep 30 / TheStreet.com - Paid Partner Content
European Stocks Rise; Oil Producers Cheer OPEC Deal, Deutsche Bank Recovers
Sep 29 / TheStreet.com - Paid Partner Content
Novo Nordisk: Long-Term Growth at a Good Price
Sep 30 / TheStreet.com - Paid Partner Content
Novo Nordisk Takes Axe to Workforce as Growth Falters
Sep 29 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close41.80
Today’s open41.58
Day’s range41.27 - 41.86
Volume5,650,527
Average volume (3 months)2,357,963
Market cap$81.9B
Dividend yield2.18%
Data as of 4:02pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+10.50%
Revenue growth (last year)+1.43%
P/E ratio2.9
Price/Sales9.38
Price/Book15.58

Competitors

 Today’s
change
Today’s
% change
CELGCelgene+1.76+1.71%
AZNAstraZeneca-0.19-0.57%
LLYEli Lilly and Co+0.52+0.65%
BMYBristol-Myers Squibb+0.05+0.09%
Data as of 4:14pm ET, 09/30/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$0.57
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts

Search for Jobs